International Journal of Technology Assessment in Health Care

ASSESSMENTS

TRANSCATHETER AORTIC VALVE IMPLANTATION FOR SEVERE AORTIC STENOSIS: THE COST-EFFECTIVENESS CASE FOR INOPERABLE PATIENTS IN THE UNITED KINGDOM

Aileen Murphya1, Elisabeth Fenwicka2, William D. Toffa3, Matthew P. Neilsona4, Colin Berrya5, Neal Urena6, Keith G. Oldroyda7 and Andrew H. Briggsa8

a1 Department of Economics, University College Cork

a2 Health Economics & Health Technology Assessment, University of Glasgow

a3 Department of Cardiovascular Services, University of Leicester

a4 Health Economics & Health Technology Assessment, University of Glasgow

a5 BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences

a6 Royal Infirmary of Edinburgh, Edinburgh Heart Centre

a7 Golden Jubilee National, West of Scotland Regional Heart & Lung Centre

a8 Health Economics & Health Technology Assessment, University of Glasgow

Aortic stenosis (AS) is caused by age-related calcific degeneration of the aortic valve (1). Initially, cases are asymptomatic but, from the point that symptoms first develop, there is rapid progression and if left untreated survival estimates are low (2–3 years) (1). Therefore, managing AS effectively and efficiently is a priority for health systems with increasing healthcare costs and longer life expectancy.

Keywords:

  • Cost-effectiveness analysis;
  • Value of information analysis;
  • EVPI;
  • EVPPI;
  • TAVI

Footnotes

  We thank members of the steering group convened for this project who informed and commented on an earlier version of the model and analysis as well as the audience at HTAi Dublin for their comments on the model.